Rita Zamarchi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/686644/publications.pdf

Version: 2024-02-01

85 papers 3,051 citations

236925
25
h-index

53 g-index

87 all docs

87 docs citations

87 times ranked

4695 citing authors

#	Article	IF	CITATIONS
1	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncology, The, 2014, 15, 406-414.	10.7	703
2	Genetic control of the CD4/CD8 T-cell ratio in humans. Nature Medicine, 1995, 1, 1279-1283.	30.7	398
3	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Critical Reviews in Oncology/Hematology, 2019, 134, 39-45.	4.4	200
4	M30 Neoepitope Expression in Epithelial Cancer: Quantification of Apoptosis in Circulating Tumor Cells by CellSearch Analysis. Clinical Cancer Research, 2010, 16, 5233-5243.	7.0	124
5	The Side Population of Ovarian Cancer Cells Is a Primary Target of IFN-α Antitumor Effects. Cancer Research, 2008, 68, 5658-5668.	0.9	121
6	Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4216-4221.	7.1	113
7	EpCAMhigh and EpCAMlow circulating tumor cells in metastatic prostate and breast cancer patients. Oncotarget, 2018, 9, 35705-35716.	1.8	70
8	Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap). International Journal of Cancer, 2018, 143, 2584-2591.	5.1	68
9	The Interplay between Circulating Tumor Cells and the Immune System: From Immune Escape to Cancer Immunotherapy. Diagnostics, 2018, 8, 59.	2.6	57
10	Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancer. British Journal of Cancer, 2012, 107, 1286-1294.	6.4	55
11	Single-Cell Analysis of Circulating Tumor Cells: How Far Have We Come in the -Omics Era?. Frontiers in Genetics, 2019, 10, 958.	2.3	53
12	Retaining the long-survive capacity of Circulating Tumor Cells (CTCs) followed by xeno-transplantation: not only from metastatic cancer of the breast but also of prostate cancer patients. Oncoscience, 2013, 1, 49-56.	2.2	52
13	Single tube liquid biopsy for advanced nonâ€small cell lung cancer. International Journal of Cancer, 2019, 144, 3127-3137.	5.1	45
14	Virus-Specific Cytotoxic CD4+ T Cells for the Treatment of EBV-Related Tumors. Journal of Immunology, 2010, 184, 5895-5902.	0.8	43
15	Differential Regulation of Hypoxia-Induced CXCR4 Triggering during B-Cell Development and Lymphomagenesis. Cancer Research, 2007, 67, 8605-8614.	0.9	41
16	Hypoxia Inducible Factor- $1\hat{l}\pm$ Inactivation Unveils a Link between Tumor Cell Metabolism and Hypoxia-Induced Cell Death. American Journal of Pathology, 2008, 173, 1186-1201.	3.8	39
17	Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. Blood, 2005, 105, 931-939.	1.4	38
18	IgG Oligoclonal Bands in Sera of HIV-1 Infected Patients Are Mainly Directed Against HIV-1 Determinants. AIDS Research and Human Retroviruses, 1990, 6, 581-586.	1.1	37

#	Article	IF	CITATIONS
19	Expression and functional activity of CXCR-4 and CCR-5 chemokine receptors in human thymocytes. Clinical and Experimental Immunology, 2002, 127, 321-330.	2.6	32
20	CD4:CD8 ratio and HIV infection: the †tap-and-drain' hypothesis. Trends in Immunology, 1996, 17, 414-417.	. 7.5	31
21	DNA copy number alterations correlate with survival of esophageal adenocarcinoma patients. Modern Pathology, 2009, 22, 58-65.	5.5	29
22	A CD3+CD8+ T Cell Population Lacking CD5 Antigen Expression Is Expanded in Peripheral Blood of Human Immunodeficiency Virus-Infected Patients. Clinical Immunology and Immunopathology, 1995, 77, 253-261.	2.0	28
23	Effects of CD2 locus control region sequences on gene expression by retroviral and lentiviral vectors. Blood, 2001, 98, 3607-3617.	1.4	28
24	Circulating and Disseminated Tumor Cells in the Clinical Management of Breast Cancer Patients: Unanswered Questions. Oncology, 2009, 76, 375-386.	1.9	27
25	B cell activation and human immunodeficiency virus infection. V. Phenotypic and functional alterations in CD5+ and CD5? B cell subsets. Journal of Clinical Immunology, 1993, 13, 381-388.	3.8	25
26	Quantitative and qualitative analysis of anti-tetanus toxoid antibody response in the elderly. Humoral immune response enhancement by thymostimulin. Vaccine, 1993, 11, 1336-1340.	3.8	25
27	Dynamic changes of Receptor activator of nuclear factor-κB expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer. Scientific Reports, 2020, 10, 1288.	3.3	25
28	Differential expression of constitutive and inducible proteasome subunits in human monocyteâ€derived DC differentiated in the presence of IFNâ€∢i>α⟨i⟩ or ILâ€4. European Journal of Immunology, 2009, 39, 56-66.	2.9	24
29	B-cell activation during HIV-1 infection. III. Down-regulating effect of mitogens. Aids, 1991, 5, 821-828.	2.2	22
30	DNA Immunization of Mice against SIVmac239 Gag and Env Using Rev-Independent Expression Plasmids. AIDS Research and Human Retroviruses, 1998, 14, 83-90.	1.1	22
31	Monitoring and Characterization of Circulating Tumor Cells (CTCs) in a Patient With EML4-ALK–Positive Non–Small Cell Lung Cancer (NSCLC). Clinical Lung Cancer, 2016, 17, e173-e177.	2.6	22
32	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. Journal of the National Cancer Institute, 2021, 113, 443-452.	6.3	22
33	First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel–Lindau (VHL) disease: clinical outcome and patterns of radiological response. Familial Cancer, 2015, 14, 309-316.	1.9	21
34	Frequency of a Mutated CCR-5 Allele (Delta32) among Italian Healthy Donors and Individuals at Risk of Parenteral HIV Infection. AIDS Research and Human Retroviruses, 1999, 15, 337-344.	1,1	20
35	Circulating tumor cells: utopia or reality?. Future Oncology, 2013, 9, 1337-1352.	2.4	20
36	Alternatively spliced forms of $\lg\hat{l}\pm$ and $\lg\hat{l}^2$ prevent B cell receptor expression on the cell surface. European Journal of Immunology, 2002, 32, 1530.	2.9	19

#	Article	IF	Citations
37	Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. Oncologist, 2021, 26, 740-750.	3.7	19
38	Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, S1346-S1358.	1.4	18
39	Possible applications of circulating tumor cells in patients with non small cell lung cancer. Lung Cancer, 2017, 107, 59-64.	2.0	17
40	A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients. Translational Lung Cancer Research, 2021, 10, 80-92.	2.8	17
41	Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial. Breast Cancer Research and Treatment, 2020, 181, 61-68.	2.5	15
42	Standardization of in vitro synthesis and detection of HIV-1-specific antibodies. Journal of Immunological Methods, 1993, 157, 105-115.	1.4	13
43	TCR Expression and Clonality Analysis in Peripheral Blood and Lymph Nodes of HIV-Infected Patients. Human Immunology, 1997, 57, 93-103.	2.4	13
44	B cell activation in peripheral blood and lymph nodes during HIV infection. Aids, 2002, 16, 1217-1226.	2.2	13
45	Detection and Prognostic Relevance of Circulating and Disseminated Tumour Cell in Dogs with Metastatic Mammary Carcinoma: A Pilot Study. Cancers, 2019, 11, 163.	3.7	13
46	Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q. Journal of Thoracic Disease, 2020, 12, 2771-2780.	1.4	13
47	Expression from cell type-specific enhancer-modified retroviral vectors after transduction: influence of marker gene stability. Gene, 2002, 283, 199-208.	2.2	11
48	Zoledronic Acid Induces a Significant Decrease of Circulating Endothelial Cells and Circulating Endothelial Precursor Cells in the Early Prostate Cancer Neoadjuvant Setting. Oncology, 2013, 85, 342-347.	1.9	11
49	Grp94 in complexes with IgG is a soluble diagnostic marker of gastrointestinal tumors and displays immune-stimulating activity on peripheral blood immune cells. Oncotarget, 2016, 7, 72923-72940.	1.8	11
50	Modulation of Moloney Leukemia Virus Long Terminal Repeat Transcriptional Activity by the Murine CD4 Silencer in Retroviral Vectors. Virology, 2000, 276, 83-92.	2.4	10
51	CD4 and CD8 T lymphocyte inheritance. Evidence for major autosomal recessive genes. Human Genetics, 1999, 105, 337-342.	3.8	10
52	Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer. Oncotarget, 2020, 11, 4115-4122.	1.8	10
53	What information could the main actors of liquid biopsy provide? $\hat{A}^{\circ}\hat{a}$, \hat{a}° representative case of non-small cell lung cancer (NSCLC). Journal of Thoracic Disease, 2018, 10, E570-E576.	1.4	9
54	Onset of HIV-1 antibody production after highly active antiretroviral therapy in a seronegative HIV-1-infected child. Aids, 2000, 14, 1284.	2.2	9

#	Article	IF	Citations
55	Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared. Journal of Thoracic Disease, 2017, 9, \$1391-\$1396.	1.4	8
56	Pediatric sarcomas display a variable EpCAM expression in a histology-dependent manner. Translational Oncology, 2020, 13, 100846.	3.7	8
57	Possible role of circulating tumor cells in early detection of lung cancer. Journal of Thoracic Disease, 2020, 12, 3821-3835.	1.4	8
58	B And T Cell Function Parameters During Zidovudine Treatment Of Human Immunodeficiency Virus-Infected Patients. Journal of Infectious Diseases, 1994, 170, 1148-1156.	4.0	7
59	Genetic variability of the human CD4 V2 domain. Immunogenetics, 1996, 44, 70-72.	2.4	7
60	Clinical significance of circulating tumor cells and cellâ€free DNA in pediatric rhabdomyosarcoma. Molecular Oncology, 2022, 16, 2071-2085.	4.6	7
61	In Vitro Spontaneous Production of Anti-SIV Antibodies Is a Reliable Tool in the Follow-Up of Protection of SIV-Vaccinated Monkeys. AIDS Research and Human Retroviruses, 1993, 9, 1139-1144.	1.1	6
62	Infection of simian B lymphoblastoid cells with simian immunodeficiency virus is associated with upregulation of CD23 and CD40 cell surface markers. Journal of Medical Virology, 2002, 68, 129-140.	5.0	6
63	Effects of glucose-regulated protein94 (Grp94) on Ig secretion from human blood mononuclear cells. Cell Stress and Chaperones, 2011, 16, 329-338.	2.9	6
64	A lymphotactin-producing monoclonal T-cell lymphoproliferative disorder with extreme lymphocytopenia and progressive leukoencephalopathy. Leukemia and Lymphoma, 2006, 47, 1421-1423.	1.3	5
65	HIV vs. the Immune System: A Differential Game. Mathematics, 2015, 3, 1139-1170.	2.2	5
66	Dysmetabolic Circulating Tumor Cells Are Prognostic in Metastatic Breast Cancer. Cancers, 2020, 12, 1005.	3.7	5
67	Cell-Secreted Vesicles: Novel Opportunities in Cancer Diagnosis, Monitoring and Treatment. Diagnostics, 2021, 11, 1118.	2.6	5
68	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. Oncologist, 2022, 27, e561-e570.	3.7	5
69	Effect of rIL-2 treatment on anti-tetanus toxoid response in the elderly. Mechanisms of Ageing and Development, 1997, 93, 205-214.	4.6	4
70	Customizing CellSearch platform. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2013, 83A, 595-598.	1.5	4
71	Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells. Melanoma Research, 2019, 29, 89-94.	1.2	4
72	Prognostic role of circulating tumor cells-CTCs in metastatic renal cell carcinoma Journal of Clinical Oncology, 2017, 35, 4568-4568.	1.6	4

#	Article	IF	CITATIONS
73	In vitro malignant progression of cells derived from Abelson murine leukaemia virus-induced thymic lymphomas. British Journal of Cancer, 1988, 58, 152-157.	6.4	3
74	Immune dysfunction in the elderly: Effect of thymic hormone administration on several in vivo and in vitro immune function parameters. Aging Clinical and Experimental Research, 1990, 2, 347-355.	2.9	3
75	Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor. Frontiers in Pediatrics, 2021, 9, 652583.	1.9	3
76	Prognostic value of circulating endothelial cells in glioblastoma patients: a pilot study. Future Science OA, 2022, 8, .	1.9	2
77	Liquid Biopsy in Pediatric Renal Cancer: Stage I and Stage IV Cases Compared. Diagnostics, 2020, 10, 810.	2.6	1
78	Mathematical models for HIV treatment: A schematic review. Journal of Interdisciplinary Mathematics, 2020, 23, 707-725.	0.7	1
79	Notes for developing a molecular test for the full characterization of circulating tumor cells. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 471-8.	2.2	1
80	Vaccination of Cynomolgus Monkeys with Whole Inactivated or Live-Attenuated Simian Immunodeficiency Virus. Antibiotics and Chemotherapy, 1996, 48, 131-138.	0.5	0
81	Reply to cole. Trends in Immunology, 1997, 18, 506-507.	7.5	0
82	Reply to Bostik et al Trends in Immunology, 1997, 18, 556.	7.5	0
83	Inhibition of immunoglobulin secretion from peripheral blood mononuclear cells by glucose-regulated protein94 (Grp94) in allergic subjects. Molecular and Cellular Biochemistry, 2012, 365, 47-52.	3.1	0
84	Circulating Tumor Cells (CTCs) and Metastatic Prostate Cancer (mPCa)., 2017,, 47-59.		0
85	Genetic variability of the human CD4 V2 domain. Immunogenetics, 1996, 44, 70-72.	2.4	O